- Home
- ANAB vs THRY Comparison
ANAB vs THRY Comparison
Compare ANAB & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- THRY
- Stock Information
- Founded
- ANAB 2005
- THRY 2003
- Country
- ANAB United States
- THRY United States
- Employees
- ANAB N/A
- THRY N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- THRY Industrial Machinery/Components
- Sector
- ANAB Health Care
- THRY Industrials
- Exchange
- ANAB Nasdaq
- THRY Nasdaq
- Market Cap
- ANAB 759.5M
- THRY 703.2M
- IPO Year
- ANAB 2017
- THRY 2020
- Fundamental
- Price
- ANAB $13.04
- THRY $14.84
- Analyst Decision
- ANAB Buy
- THRY Strong Buy
- Analyst Count
- ANAB 11
- THRY 3
- Target Price
- ANAB $42.67
- THRY $24.33
- AVG Volume (30 Days)
- ANAB 775.9K
- THRY 587.3K
- Earning Date
- ANAB 11-05-2024
- THRY 02-20-2025
- Dividend Yield
- ANAB N/A
- THRY N/A
- EPS Growth
- ANAB N/A
- THRY N/A
- EPS
- ANAB N/A
- THRY N/A
- Revenue
- ANAB $57,172,000.00
- THRY $873,723,000.00
- Revenue This Year
- ANAB $233.68
- THRY N/A
- Revenue Next Year
- ANAB N/A
- THRY N/A
- P/E Ratio
- ANAB N/A
- THRY N/A
- Revenue Growth
- ANAB 282.17
- THRY N/A
- 52 Week Low
- ANAB $13.00
- THRY $13.06
- 52 Week High
- ANAB $41.31
- THRY $26.42
- Technical
- Relative Strength Index (RSI)
- ANAB 27.77
- THRY 45.56
- Support Level
- ANAB $15.11
- THRY $13.76
- Resistance Level
- ANAB $16.74
- THRY $14.96
- Average True Range (ATR)
- ANAB 1.48
- THRY 0.69
- MACD
- ANAB -0.31
- THRY -0.11
- Stochastic Oscillator
- ANAB 0.31
- THRY 35.06
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About THRY Thryv Holdings Inc.
Thryv Holdings Inc provides software as service (SaaS) management tools and digital and print marketing tools to small and mid-sized businesses. The company operates in four reportable segments namely Thryv U.S. Marketing Services, Thryv U.S. SaaS, Thryv International Marketing Services, and Thryv International SaaS. It generates maximum revenue from the Thryv U.S. Marketing Services segment.